## **Core Concept**
Maroteaux-Lamy syndrome, also known as **Mucopolysaccharidosis type VI (MPS VI)**, is a rare genetic disorder caused by a deficiency of a specific enzyme involved in the breakdown of glycosaminoglycans (GAGs). This condition leads to the accumulation of GAGs within cells and tissues, resulting in various clinical manifestations.

## **Why the Correct Answer is Right**
The correct answer, **N-acetylgalactosamine-4-sulfatase (arylsulfatase B)**, is the enzyme deficient in Maroteaux-Lamy syndrome. This enzyme plays a crucial role in the degradation pathway of dermatan sulfate and chondroitin-4-sulfate, which are types of GAGs. The deficiency of arylsulfatase B leads to the accumulation of these GAGs, causing the clinical features of MPS VI, such as short stature, facial dysmorphism, joint stiffness, and corneal clouding.

## **Why Each Wrong Option is Incorrect**
- **Option A:** **α-L-iduronidase** is deficient in Hurler syndrome (MPS I) and Scheie syndrome (MPS I S), not Maroteaux-Lamy syndrome.
- **Option B:** **α-N-acetylglucosaminidase** is associated with Sanfilippo syndrome type B (MPS III B), not Maroteaux-Lamy syndrome.
- **Option D:** **Glucosamine-6-sulfatase** is related to metachromatic leukodystrophy or a condition affecting the degradation of heparan sulfate and not directly linked to Maroteaux-Lamy syndrome.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl for Maroteaux-Lamy syndrome is that patients often present with **corneal clouding**, which is a significant diagnostic clue. Additionally, the condition is characterized by a **variable degree of severity**, ranging from a severe form with early onset to a milder form with later onset and fewer symptoms.

## **Correct Answer:** . **N-acetylgalactosamine-4-sulfatase (arylsulfatase B)**